TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01975727

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo (saline 0.9%)
Study: NCT03793270

Intervention type: DIAGNOSTIC_TEST
Intervention: for patients and healthy donors
Description: 1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate
Study: NCT01975727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 3 mg
Description: 10 ml Seringue with Dexamethasone
Study: NCT03793270

Intervention type: DIAGNOSTIC_TEST
Intervention: for patients and healthy donors
Description: 1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate

Intervention type: DIAGNOSTIC_TEST
Intervention: for patients and healthy donors
Description: 1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate
Study: NCT04576273

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology examination
Description: Gross and microscopic evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology examination
Description: Gross and microscopic evaluation
Study: NCT03695120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change of treatment plan
Description: Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
Study: NCT00824239

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent sedation
Description: Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Daily interruption of sedation
Description: Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
Study: NCT02205632

Intervention type: DEVICE
Group type: OTHER
Intervention: MPS II

Intervention type: DEVICE
Group type: OTHER
Intervention: MPS II
Study: NCT03921671

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
Study: NCT06175910

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotomy
Description: A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrograde intrarenal surgery
Description: urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied.
Study: NCT01008488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Antibiotic according to local treatment routine against bowel pathogenesis
Study: NCT03438344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-antigen CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IM
Study: NCT02984709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Health Behavior Contract - Baseline visit Education Packet - Baseline visit
Study: NCT05221515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger can go!
Description: The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent psycho-education
Description: Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent psycho-education
Description: Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
Study: NCT04938804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography
Description: The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
Study: NCT01932112

Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine arm
Description: After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
Study: NCT03565926

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: 1. Articulation technique L4-S1~2. Lumbar neuromuscular technique~3. Fascial technique of crossed hands~4. Posteroanterior mobilizations of the lumbar vertebrae

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Description: Protocol 5 Hypopressive exercises
Study: NCT00865358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Group
Description: Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
Study: NCT00118924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LGT(TP21)/DEN4
Description: Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LGT(TP21)/DEN4
Description: Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for LGT(TP21)/DEN4 vaccine
Study: NCT02559115

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2 (RM2)
Study: NCT01540526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 7 mg PO BID days 1-14 in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 7 mg PO BID days 1-14 in 21 day cycles.
Study: NCT02048644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostair
Description: beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matched inhaler 2puffs to be taken twice a day for 28 days
Study: NCT02052661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Single dose administered intramuscularly in deltoid region of non-dominant arm.
Study: NCT00420082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Encapsulated Bilastine 20 mg tablets Q.D.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Encapsulated Fexofenadine 120 mg tablets Q.D.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Encapsulated Cetirizine 10 mg tablets Q.D.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated Placebo tablets Q.D.
Study: NCT04548570

Intervention type: PROCEDURE
Intervention: approximation of both rectus muscles
Description: closure of both rectus muscle before closure of rectus sheeth

Intervention type: PROCEDURE
Intervention: approximation of both rectus muscles
Description: closure of both rectus muscle before closure of rectus sheeth
Study: NCT01975727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 6 mg
Description: 10 ml Seringue with Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 12 mg
Description: 10 ml Seringue with Dexamethasone
Study: NCT02857751

Intervention type: BEHAVIORAL
Intervention: Surf therapy
Description: The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
Study: NCT02559115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Study: NCT02857751

Intervention type: BEHAVIORAL
Intervention: Surf therapy
Description: The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.

Intervention type: BEHAVIORAL
Intervention: Surf therapy
Description: The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.

Intervention type: BEHAVIORAL
Intervention: Surf therapy
Description: The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.

Intervention type: BEHAVIORAL
Intervention: Surf therapy
Description: The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
Study: NCT03384082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic treatment
Description: treatment
Study: NCT04270318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CH Pulpotomy, physiologic saline
Description: Pulp chamber was cleansed with physiologic saline for 30 s.
Study: NCT02130635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 100 MCG
Description: 100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
Study: NCT04270318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CH pulpotomy, NaOCl
Description: Pulp chamber was cleansed with 5 % NaOCl for 30 s.
Study: NCT02130635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 100 MCG
Description: 100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 100 MCG
Description: 100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 500 MCG
Description: 500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 500 MCG
Description: 500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 500 MCG
Description: 500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 500 MCG
Description: 500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
Study: NCT04270318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA Pulpotomy, physiologic saline
Description: Pulp chamber was cleansed with physiologic saline for 30 s.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTA pulpotomy, NaOCl
Description: Pulp chamber was cleansed with 5 % NaOCl for 30 s.
Study: NCT02130635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 500 MCG
Description: 500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device
Study: NCT03631849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri implantitis sanitation surgery
Description: an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care
Description: descaling and maintenance of implants
Study: NCT03188133

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: behavioral task : emotional priming
Description: emotional priming task on ambiguous visual stimuli

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: behavioral task : emotional priming
Description: emotional priming task on ambiguous visual stimuli

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavioral task : emotional priming
Description: emotional priming task on ambiguous visual stimuli
Study: NCT00499161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New model of nursing care
Study: NCT01726504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electro-acupuncture
Description: Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
Study: NCT00956800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accu-Chek 360 software
Description: Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal care
Description: Control group will receive 5 routine office visits in one year
Study: NCT01173081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20mcg once daily for 16 weeks or until study endpoint is achieved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
Study: NCT00213135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine 5.25 mg/kg
Description: Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Description: Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.